Drugs · Entity Annotation Prototype (beta)

4articles mentioning drugs

4drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: prednisone-equivalent ×

prednisone-equivalent

This drug is selected. Its supporting articles are shown below.

prednisone-equivalent4

Articles mentioning prednisone-equivalent

4 articles · page 1 of 1

PO:11:298 Belimumab is associated with lower risk of progression to LN compared with standard of care in patients with SLE

lupusscimed · abstract · 2026-03-01 · 1 matching annotations

91.5%

belimumab voclosporin prednisone-equivalent cyclophosphamide SLE LN

…ndings suggest potential renal protective effects through which belimumab may prevent progression to LN.Funding: GSKOriginal presentation…

PT3:01 Feasibility of extrarenal systemic lupus erythematosus disease modification in GLADEL 2.0, a Latin American cohort

lupusscimed · abstract · 2026-03-01 · 1 matching annotations

95.7%

cyclophosphamide prednisone prednisone-equivalent SLE

…y a significant role in extrarenal DM achievement, particularly cyclophosphamide. These results underscore the importance of addressing SDH and …

PT3:03 Rapid Oral glucocorticoid discontinuation or dose reduction among US patients with SLE receiving belimumab in a real-world setting

lupusscimed · abstract · 2026-03-01 · 1 matching annotations

85.5%

Belimumab prednisone-equivalent BEL OGC SLE lupus

…Objectives Belimumab (BEL), a B-cell modulator mAb that selectively inhibits soluble…

S7:05 Ability of SLE-DAS and SLEDAI-2K to predict organ damage accrual in SLE: a real-world 7-year cohort study from Sweden

lupusscimed · abstract · 2026-03-01 · 1 matching annotations

81.6%

prednisone-equivalent Systemic lupus erythematosus SLE-DAS SLE KLURING

…els, along with age and sex as covariates fixed at baseline and prednisone-equivalent dose as a time-dependent variable. Models were applied for 3, 5…

Browse drugs

prednisone-equivalent

Articles mentioning prednisone-equivalent

PO:11:298 Belimumab is associated with lower risk of progression to LN compared with standard of care in patients with SLE

PT3:01 Feasibility of extrarenal systemic lupus erythematosus disease modification in GLADEL 2.0, a Latin American cohort

PT3:03 Rapid Oral glucocorticoid discontinuation or dose reduction among US patients with SLE receiving belimumab in a real-world setting

S7:05 Ability of SLE-DAS and SLEDAI-2K to predict organ damage accrual in SLE: a real-world 7-year cohort study from Sweden